Author details

Full Name

Abraham Ari Hakimi

Affiliation

ORCID

Career Start Year

2004

Papers

217

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37423816	Adverse pathologic features impact survival outcomes for small renal masses following nephrectomy.	Urol Oncol	2023
36424079	Current and Future Biomarkers in the Management of Renal Cell Carcinoma.	Urologic Clinics of North America	2023
37589200	Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.		2023
37416962	Reply by Authors.		2023
37413991	Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.	Cell Metab	2023
37337120	A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation.	Nat Metab	2023
37185232	Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma.	J Immunother Cancer	2023
37058796	Gossypiboma of thigh mimicking soft tissue sarcoma: A case report and review of the literature.		2023
36863962	Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.	Eur Urol Focus	2023
36793052	Sarcomatoid renal cell carcinoma: MRI features and their association with survival.		2023
36672304	Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature.		2023
36603175	Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.	J Clin Oncol	2023
36724067	Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.		2023
37517254	Primary intramuscular thigh hydatid cyst: A case report.		2023
37541245	Chromophobe renal cell carcinoma	Cancer Cell	2023
34965942	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.	Clin Cancer Res	2022
35837094	Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.	Frontiers in Oncology	2022
35705800	Author Correction: Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.	Nat Immunol	2022
35762219	A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes.	J Urol	2022
36288724	Tumor-associated macrophages expressing the transcription factor IRF8 promote TÂ cell exhaustion in cancer.	Immunity	2022
35758895	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.	Cancer Discov	2022
35753989	Systemic Immunological Determinants of Oncological Outcomes After Surgery for Localized Renal Cell Carcinoma.		2022
35942787	Reply by Authors.	J Urol	2022
35942785	Reply by Authors.	J Urol	2022
35565216	Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.	Cancers	2022
35618834	Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies.	Nat Immunol	2022
36065259	Prevalence, Distribution, and Histopathological Features of Malignant Tumors Reported at Tertiary Level in Afghanistan: A 3-Year Study.	Cancer Management and Research	2022
35984355	XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL.	Clinical Cancer Research	2022
36190538	Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.	Clin Cancer Res	2022
36536472	Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.	Genome Med	2022
35288096	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.	Eur Urol Focus	2022
35247895	Rules of Engagement: The Lymphocyte Receptor Ecosystem in Renal Cell Carcinoma.	Cancer Research	2022
34654685	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing.	Eur Urol Oncol	2021
31813809	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.	Eur Urol Focus	2021
33861994	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂ cells in ccRCC to tumor topology and therapy efficacy.	Cancer Cell	2021
34123789	Uncontrolled Confounders May Lead to False or Overvalued Radiomics Signature: A Proof of Concept Using Survival Analysis in a Multicenter Cohort of Kidney Cancer.	Frontiers in Oncology	2021
33853747	Open partial nephrectomy with kidney split: Effective surgical approach to resect completely endophytic tumors.	Urologic Oncology: Seminars and Original Investigations	2021
34286865	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.	Cancer	2021
33848068	A comparison of oncologic and functional outcomes in patients with pt3a renal cell carcinoma treated with partial and radical nephrectomy.	International braz j urol : official journal of the Brazilian Society of Urology	2021
34058014	Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma.	Int J Cancer	2021
33625877	OncoTree: A Cancer Classification System for Precision Oncology.	JCO Clin Cancer Inform	2021
33526794	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.	Nat Commun	2021
33779820	A qualitative framework of non-selection factors for cytoreductive nephrectomy.	World Journal of Urology	2021
34261695	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.	Clin Cancer Res	2021
33833465	Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA.	Nat Metab	2021
34039647	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.	Mol Cancer Res	2021
33658299	Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.	Clinical Cancer Research	2021
34344758	Chemerin Tips the Scales in ccRCC to Evade Ferroptosis.	Cancer Discovery	2021
34343338	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.	Cancer	2021
34331997	Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management.	Urology	2021